英夫利昔单抗会增加炎症性肠病手术后的并发症吗？
Does infliximab increase complications after surgery for inflammatory bowel disease?
作者信息
Holubar Stefan D, Cima Robert R, Pemberton John H
机构信息
Division of Colon and Rectal Surgery, Mayo Clinic 200 First Street SW, Rochester, MN 55905 USA.
出版信息
F1000 Med Rep. 2009 Jan 21;1:10. doi: 10.3410/M1-10.
Abstract
Conflicting data exist regarding the association between pre-operative monoclonal anti-tumor necrosis factor-alpha antibody therapy with infliximab for Crohn disease and chronic ulcerative colitis, and the occurrence of post-operative complications. This report reviews the current literature that supports and refutes this association.
摘要
关于克罗恩病和慢性溃疡性结肠炎患者术前使用英夫利昔单抗进行单克隆抗肿瘤坏死因子-α抗体治疗与术后并发症发生之间的关联，存在相互矛盾的数据。本报告回顾了支持和反驳这一关联的当前文献。
相似文献
1
Does infliximab increase complications after surgery for inflammatory bowel disease?英夫利昔单抗会增加炎症性肠病手术后的并发症吗？
F1000 Med Rep. 2009 Jan 21;1:10. doi: 10.3410/M1-10.
2
Visceral adiposity and inflammatory bowel disease.内脏肥胖与炎症性肠病。
Int J Colorectal Dis. 2021 Nov;36(11):2305-2319. doi: 10.1007/s00384-021-03968-w. Epub 2021 Jun 9.
3
[Long-term follow-up of inflammatory bowel disease patients receiving anti-tumor necrosis factor-alpha therapy].接受抗肿瘤坏死因子-α治疗的炎症性肠病患者的长期随访
Orv Hetil. 2020 Nov 22;161(47):1989-1994. doi: 10.1556/650.2020.31913.
4
Management of inflammatory bowel disease with infliximab and other anti-tumor necrosis factor alpha therapies.英夫利昔单抗和其他抗肿瘤坏死因子 α 治疗药物治疗炎症性肠病。
BioDrugs. 2010 Dec 14;24 Suppl 1:3-14. doi: 10.2165/11586290-000000000-00000.
5
Generalized Pyoderma Gangrenosum Associated with Ulcerative Colitis: Successful Treatment with Infliximab and Azathioprine.与溃疡性结肠炎相关的泛发性坏疽性脓皮病：英夫利昔单抗和硫唑嘌呤治疗成功
Acta Dermatovenerol Croat. 2016 Apr;24(1):83-5.
6
Tumour necrosis factor-alpha receptor 1 and 2 polymorphisms in inflammatory bowel disease and their association with response to infliximab.炎症性肠病中肿瘤坏死因子-α受体1和2的多态性及其与英夫利昔单抗反应的关联。
Aliment Pharmacol Ther. 2004 Aug 1;20(3):303-10. doi: 10.1111/j.1365-2036.2004.01946.x.
7
Meta-analysis: pre-operative infliximab treatment and short-term post-operative complications in patients with ulcerative colitis.Meta 分析：英夫利昔单抗术前治疗与溃疡性结肠炎患者短期术后并发症的关系。
Aliment Pharmacol Ther. 2010 Feb 15;31(4):486-92. doi: 10.1111/j.1365-2036.2009.04204.x. Epub 2009 Nov 19.
8
IMPORTANCE OF MEASURING LEVELS OF INFLIXIMAB IN PATIENTS TREATING INFLAMMATORY BOWEL DISEASE IN A BRAZILIAN COHORT.在巴西队列中测量接受炎症性肠病治疗患者的英夫利昔单抗水平的重要性。
Arq Gastroenterol. 2017 Dec;54(4):333-337. doi: 10.1590/S0004-2803.201700000-41. Epub 2017 Sep 21.
9
[Does conservative therapy of chronic inflammatory bowel diseases still play a role?].
Swiss Surg. 2003;9(3):127-30. doi: 10.1024/1023-9332.9.3.127.
10
Safe and effective: anti-tumour necrosis factor therapy use in pregnant patients with Crohn disease and ulcerative colitis.安全且有效：抗肿瘤坏死因子疗法在克罗恩病和溃疡性结肠炎孕妇患者中的应用
Intern Med J. 2016 May;46(5):616-9. doi: 10.1111/imj.13057.
引用本文的文献
1
A review of the impact of biologics on surgical complications in Crohn's disease.生物制剂对克罗恩病手术并发症影响的综述。
Inflamm Bowel Dis. 2015 Jun;21(6):1472-7. doi: 10.1097/MIB.0000000000000362.
2
Surgical risks in patients on inflammatory bowel disease medications.接受炎症性肠病药物治疗患者的手术风险。
Gastroenterol Hepatol (N Y). 2011 Apr;7(4):246-7.
3
Inflammatory bowel disease: perioperative pharmacological considerations.炎症性肠病：围手术期药理学考虑。
Mayo Clin Proc. 2011 Aug;86(8):748-57. doi: 10.4065/mcp.2011.0074.
4
[Perioperative use of biologicals in rheumatoid arthritis].[生物制剂在类风湿关节炎围手术期的应用]
Z Rheumatol. 2011 Jan;70(1):14-20. doi: 10.1007/s00393-010-0680-7.
5
Long-term direct costs before and after proctocolectomy for ulcerative colitis: a population-based study in Olmsted County, Minnesota.溃疡性结肠炎直肠结肠切除术前及术后长期直接费用：明尼苏达州奥姆斯特德县的一项基于人群的研究。
Dis Colon Rectum. 2009 Nov;52(11):1815-23. doi: 10.1007/DCR.0b013e3181b327a6.
本文引用的文献
1
Perioperative treatment with infliximab in patients with Crohn's disease and ulcerative colitis is not associated with an increased rate of postoperative complications.在克罗恩病和溃疡性结肠炎患者中，围手术期使用英夫利昔单抗与术后并发症发生率升高无关。
J Gastrointest Surg. 2008 Oct;12(10):1730-6; discussion 1736-7. doi: 10.1007/s11605-008-0630-8. Epub 2008 Aug 16.
2
Use of infliximab within 3 months of ileocolonic resection is associated with adverse postoperative outcomes in Crohn's patients.在回结肠切除术后3个月内使用英夫利昔单抗与克罗恩病患者术后不良结局相关。
J Gastrointest Surg. 2008 Oct;12(10):1738-44. doi: 10.1007/s11605-008-0646-0. Epub 2008 Aug 15.
3
Infliximab pharmacokinetics in inflammatory bowel disease patients.英夫利昔单抗在炎症性肠病患者中的药代动力学。
Ther Drug Monit. 2008 Aug;30(4):523-9. doi: 10.1097/FTD.0b013e318180e300.
4
Infliximab in ulcerative colitis is associated with an increased risk of postoperative complications after restorative proctocolectomy.英夫利昔单抗治疗溃疡性结肠炎与全直肠系膜切除术后并发症风险增加相关。
Dis Colon Rectum. 2008 Aug;51(8):1202-7; discussion 1207-10. doi: 10.1007/s10350-008-9364-7. Epub 2008 Jun 7.
5
Positioning biologic therapy for Crohn's disease and ulcerative colitis.克罗恩病和溃疡性结肠炎生物疗法的定位
Curr Gastroenterol Rep. 2007 Dec;9(6):521-7. doi: 10.1007/s11894-007-0069-1.
6
Medical therapy for Crohn's disease: top-down or step-up?克罗恩病的药物治疗：自上而下还是逐步升级？
Dig Dis. 2007;25(3):260-6. doi: 10.1159/000103897.
7
Does infliximab influence surgical morbidity of ileal pouch-anal anastomosis in patients with ulcerative colitis?英夫利昔单抗对溃疡性结肠炎患者回肠储袋肛管吻合术的手术并发症有影响吗？
Dis Colon Rectum. 2007 Nov;50(11):1747-53. doi: 10.1007/s10350-007-9008-3.
8
Clinical pharmacokinetics and use of infliximab.英夫利昔单抗的临床药代动力学及应用
Clin Pharmacokinet. 2007;46(8):645-60. doi: 10.2165/00003088-200746080-00002.
9
Coccidioidomycosis pneumonia in a nonendemic area associated with infliximab.非流行地区与英夫利昔单抗相关的球孢子菌病肺炎
South Med J. 2007 May;100(5):517-8. doi: 10.1097/01.smj.0000242797.49218.44.
10
The impact of preoperative immunomodulation on pouch-related septic complications after ileal pouch-anal anastomosis.术前免疫调节对回肠储袋肛管吻合术后储袋相关感染性并发症的影响。
Dis Colon Rectum. 2007 Jul;50(7):943-51. doi: 10.1007/s10350-007-0246-1.
Zotero 插件